CEP55 Antibody

1. A significant over expression of forkhead box protein M1 (FOXM1), polo-like kinase 1 (PLK1) and centrosomal protein 55 (CEP55) was observed in tumor samples compared to adjacent and normal bladder tissues, suggesting they may be potential candidate's biomarkers for early diagnosis and targets for cancer therapy. PMID: 30277841
2. our data suggest that CEP55 can be used as a prognostic marker for osteosarcoma PMID: 29579156
3. CEP55 was increased in lung cancer cells. PMID: 29750778
4. whole-exome sequencing lead to identification of a homozygous nonsense mutation c.256C>T (p.Arg86*) in CEP55 (centrosomal protein of 55 kDa) in autosomal recessive Meckel syndrome fetus. PMID: 28295209
5. CEP55 loss of function mutations likely underlie MARCH, a novel multiple congenital anomaly syndrome. PMID: 28264986
6. A FAK-Src signaling pathway downstream of integrin-mediated cell adhesion was found to decelerate both PLK1 degradation and CEP55 accumulation at the midbody. These data identify the regulation of PLK1 and CEP55 as steps where integrins exert control over the cytokinetic abscission. PMID: 27127172
7. Data suggest that USP9X as an integral component of centrosome where it functions to stabilize PCM1 and CEP55 and to promote centrosome biogenesis; N-terminal domain of USP9X appears to be responsible for physical association of USP9X with PCM1 and CEP55. (USP9X = ubiquitin-specific protease 9X; PCM1 = pericentriolar material 1 protein; CEP55 = 55kDa centrosomal protein) PMID: 28620049
8. Aberrant CEP55 expression may predict unfavorable clinical outcomes in epithelial ovarian carcinoma (EOC) patients and play an important role in regulating invasion in ovarian cancer cells. Thus, CEP55 may serve as a prognostic marker and therapeutic target for EOC PMID: 26615423
9. CEP55 plays a crucial role in promoting breast cancer cell proliferation and it might be a potential therapeutic target in breast cancer. PMID: 26902787
10. In depth discussion of the functions of CEP55 across different effector pathways, and also its roles as a biomarker and driver of tumorigenesis, commemorating a decade of research on CEP55. [review] PMID: 25915844
11. Which was required for FLJ10540/MMP-7 or FLJ10540/MMP-10 expressions. PMID: 25889801
12. myotubularin-related protein 3 and myotubularin-related protein 4 may act as a bridge between CEP55 and polo-like kinase 1, ensuring proper CEP55 phosphorylation and regulating CEP55 recruitment to the midbody. PMID: 25659891
13. CEP55 mRNA/protein expression was observed is specific to TCC of human urinary bladder and might be used as a diagnostic biomarker and vaccine target in development of BC specific immunotherapy. PMID: 25178936
14. cellular proliferation was suppressed as a result of cell cycle arrest at the G2/M phase in CEP55-knockdown cells PMID: 24390615
15. FLJ10540 may be critical regulator of disease progression in nasopharygeal carcinoma, and the underlying mechanism may involve in the osteopontin/CD44 pathway. PMID: 22591637
16. At the midbody, BRCA2 influences the recruitment of endosomal sorting complex required for transport (ESCRT)-associated proteins, Alix and Tsg101, and formation of CEP55-Alix and CEP55-Tsg101 complexes during abscission. PMID: 22771033
17. the existence of a p53-Plk1-Cep55 axis in which p53 negatively regulates expression of Cep55, through Plk1 which, in turn, is a positive regulator of Cep55 protein stability. PMID: 22184120
18. Data provide strong evidence that CEP55 and HELLS may be used in conjunction with FOXM1 as a biomarker set for early cancer detection and indicators of malignant conversion and progression. PMID: 20400365
19. Data show that Plk1 activity negatively regulates Cep55 to ensure orderly abscission factor recruitment and ensures that this occurs only once cell contraction has completed. PMID: 21079244
20. Cep55 is stabilized in a phosphorylation- and Pin1-dependent manner. PMID: 19855176
21. data suggest a possible involvement of CEP55 in centrosome-dependent cellular functions, such as centrosome duplication and/or cell cycle progression, or in the regulation of cytokinesis PMID: 16406728
22. This study defines a cellular mechanism that links centralspindlin to Cep55, which, in turn, controls the midbody structure and membrane fusion at the terminal stage of cytokinesis. PMID: 16790497
23. By forming a complex with phosphatidylinositol 3'-kinase, FLJ10540 activates the PI3-kinase/AKT proto-oncogene protein pathways, providing a mechanistic basis for FLJ10540-mediated oncogenesis. PMID: 17237822
24. study shows that two proteins involved in HIV-1 budding-Tsg101, a subunit of the endosomal sorting complex required for transport I (ESCRT-I), & Alix, an ESCRT-associated protein-were recruited to the midbody during cytokinesis by interaction with Cep55 PMID: 17556548
25. that ALIX and TSG101/ESCRT-I also bind a series of proteins involved in cytokinesis, including CEP55, CD2AP, ROCK1, and IQGAP1. PMID: 17853893
26. the Cep55/Alix/ESCRT-III pathway has a role in cytokinesis and HIV-1 release PMID: 18641129
27. crystal structure of the ESCRT and ALIX-binding region (EABR) of CEP55 bound to an ALIX peptide at a resolution of 2.0 angstroms; structure shows that EABR forms an aberrant dimeric parallel coiled coil PMID: 18948538
28. FLJ10540 is not only an important prognostic factor but also a new therapeutic target in the FLJ10540/FOXM1/MMP-2 pathway for oral cavity squamous cell carcinoma treatment. PMID: 19525975
29. protein could be detected in breast- and lung carcinoma 9but not normal) tissues PMID: 19609239

Show More

Hide All

HGNC: 1161

OMIM: 236500

KEGG: hsa:55165

STRING: 9606.ENSP00000360540

UniGene: Hs.14559